Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults

Graceway Pharmaceuticals, LLC88 enrolled

Overview

The primary purpose of this study is to evaluate the effectiveness in adults, of four different strengths of resiquimod gel applied to common wart(s) three times a week for twelve weeks. A second purpose is to evaluate the safety of the drug.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Warts

Interventions

ResiquimodDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of common warts * Two forms of birth control Exclusion Criteria: * Pregnant or breast feeding * Other types of wart(s), ie. plantar * Currently participating in another clinical study * Chronic viral hepatitis B or C

Locations (1)

Welborn Clinic

Evansville, Indiana, United States

Outcomes

Primary Outcomes

Clearance of treated common wart(s)

Secondary Outcomes

Partial clearance of treated common wart(s)

Wart recurrence

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.